Cytokine and angiogenic factors associated with efficacy and toxicity of pazopanib in advanced soft-tissue sarcoma: an EORTC-STBSG study (Q34340390)

From Wikidata

Jump to navigation Jump to search

The printable version is no longer supported and may have rendering errors. Please update your browser bookmarks and please use the default browser print function instead.

scientific article

Language	Label	Description	Also known as
English	Cytokine and angiogenic factors associated with efficacy and toxicity of pazopanib in advanced soft-tissue sarcoma: an EORTC-STBSG study	scientific article

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

1 August 2017

Cytokine and angiogenic factors associated with efficacy and toxicity of pazopanib in advanced soft-tissue sarcoma: an EORTC-STBSG study (English)

1 reference

Europe PubMed Central

PubMed publication ID

1 August 2017

6

object named as

A Le Cesne

0 references

5

object named as

J-Y Blay

0 references

author name string

S Sleijfer

1

1 reference

Europe PubMed Central

PubMed publication ID

1 August 2017

T Gorlia

2

1 reference

Europe PubMed Central

PubMed publication ID

1 August 2017

C Lamers

3

1 reference

Europe PubMed Central

PubMed publication ID

1 August 2017

H Burger

4

1 reference

Europe PubMed Central

PubMed publication ID

1 August 2017

M Scurr

7

1 reference

Europe PubMed Central

PubMed publication ID

1 August 2017

F Collin

8

1 reference

Europe PubMed Central

PubMed publication ID

1 August 2017

L Pandite

9

1 reference

Europe PubMed Central

PubMed publication ID

1 August 2017

S Marreaud

10

1 reference

Europe PubMed Central

PubMed publication ID

1 August 2017

P Hohenberger

11

1 reference

Europe PubMed Central

PubMed publication ID

1 August 2017

language of work or name

0 references

publication date

17 July 2012

1 reference

Europe PubMed Central

PubMed publication ID

1 August 2017

British Journal of Cancer

1 reference

Europe PubMed Central

PubMed publication ID

1 August 2017

107

1 reference

Europe PubMed Central

PubMed publication ID

1 August 2017

4

1 reference

Europe PubMed Central

PubMed publication ID

1 August 2017

639-645

1 reference

Europe PubMed Central

PubMed publication ID

1 August 2017

Biomarkers as predictors of response to treatment with motesanib in patients with progressive advanced thyroid cancer.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3419967

6 July 2018

(Pre-)clinical pharmacology and activity of pazopanib, a novel multikinase angiogenesis inhibitor

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3419967

6 July 2018

Plasma cytokine and angiogenic factor profiling identifies markers associated with tumor shrinkage in early-stage non-small cell lung cancer patients treated with pazopanib

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3419967

6 July 2018

Biomarkers of angiogenesis and their role in the development of VEGF inhibitors

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3419967

6 July 2018

Distinct patterns of cytokine and angiogenic factor modulation and markers of benefit for vandetanib and/or chemotherapy in patients with non-small-cell lung cancer.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3419967

6 July 2018

Efficacy and safety of trabectedin in patients with advanced or metastatic liposarcoma or leiomyosarcoma after failure of prior anthracyclines and ifosfamide: results of a randomized phase II study of two different schedules

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3419967

6 July 2018

Pazopanib, a multikinase angiogenesis inhibitor, in patients with relapsed or refractory advanced soft tissue sarcoma: a phase II study from the European organisation for research and treatment of cancer-soft tissue and bone sarcoma group (EORTC stu

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3419967

6 July 2018

FLT1 and its ligands VEGFB and PlGF: drug targets for anti-angiogenic therapy?

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3419967

6 July 2018

The pharmacologic basis of ifosfamide use in adult patients with advanced soft tissue sarcomas

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3419967

6 July 2018

Multiple circulating proangiogenic factors induced by sunitinib malate are tumor-independent and correlate with antitumor efficacy

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3419967

6 July 2018

Safety, pharmacokinetics, and efficacy of AMG 706, an oral multikinase inhibitor, in patients with advanced solid tumors

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3419967

6 July 2018

Using single-agent therapy in adult patients with advanced soft tissue sarcoma can still be considered standard care

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3419967

6 July 2018

Progression-free survival in gastrointestinal stromal tumours with high-dose imatinib: randomised trial

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3419967

6 July 2018

Soluble markers for the assessment of biological activity with PTK787/ZK 222584 (PTK/ZK), a vascular endothelial growth factor receptor (VEGFR) tyrosine kinase inhibitor in patients with advanced colorectal cancer from two phase I trials

1 reference

https://api.crossref.org/works/10.1038%2FBJC.2012.328

21 January 2018

Paclitaxel in the treatment of patients with angiosarcoma of the scalp or face.

1 reference

https://api.crossref.org/works/10.1038%2FBJC.2012.328

21 January 2018

Baseline vascular endothelial growth factor concentration as a potential predictive marker of benefit from vandetanib in non-small cell lung cancer.

1 reference

https://api.crossref.org/works/10.1038%2FBJC.2012.328

21 January 2018

A randomized, double-blind, phase IIa dose-finding study of Vandetanib (ZD6474) in Japanese patients with non-small cell lung cancer

1 reference

https://api.crossref.org/works/10.1038%2FBJC.2012.328

21 January 2018

Antitumor activity and biomarker analysis of sunitinib in patients with bevacizumab-refractory metastatic renal cell carcinoma.

1 reference

https://api.crossref.org/works/10.1038%2FBJC.2012.328

21 January 2018

Identifiers

10.1038/BJC.2012.328

1 reference

Europe PubMed Central

PubMed publication ID

1 August 2017

Dimensions Publication ID

0 references

PMC publication ID

1 reference

Europe PubMed Central

PubMed publication ID

1 August 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

1 August 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q34340390&oldid=2196524421"